First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
出版年份 2022 全文链接
标题
First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-02-10
DOI
10.3389/fphar.2022.821363
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study
- (2021) Dominic Beale et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
- (2021) Dirk Thomas et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty
- (2020) Jeffrey I. Weitz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Therapeutic strategies for thrombosis: new targets and approaches
- (2020) Nigel Mackman et al. NATURE REVIEWS DRUG DISCOVERY
- MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans
- (2019) Alexander W. Koch et al. BLOOD
- Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial
- (2019) Christina U. Lorentz et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects
- (2018) Vidya Perera et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality
- (2018) Taku Inohara et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?
- (2018) Felice Gragnano et al. EUROPEAN HEART JOURNAL
- Factor XI as a Therapeutic TargetHighlights
- (2016) David Gailani et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events
- (2016) Meir Preis et al. BLOOD
- Global Burden of Thrombosis: Table.
- (2016) Aaron M. Wendelboe et al. CIRCULATION RESEARCH
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
- (2015) Harry R. Büller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing bleeding risk in patients taking anticoagulants
- (2013) Marwa Shoeb et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Inhibition of Factor XIa as a New Approach to Anticoagulation
- (2010) William A. Schumacher et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Coagulation factor XI as a novel target for antithrombotic treatment
- (2010) E. C. LÖWENBERG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis
- (2010) Ophira Salomon et al. THROMBOSIS AND HAEMOSTASIS
- Reduced incidence of ischemic stroke in patients with severe factor XI deficiency
- (2008) O. Salomon et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started